Eric Evans: Yeah. So great, great questions. Let me start with the first question. So the non-consolidated deals are actually even higher acuity in totality than our current book of business. So we’ve used it as a way to expand into those procedures that matter most. So the answer there is, from a directional mix perspective, that’s true. We’ve also, like I said, been very pleased with the early growth we’re driving in those facilities. Both proves our value and also taking advantage of the synergies we bring to those facilities. So as we’ve talked about before, we were getting accounting for a second, we’re going to make the best earnings decision for the company. and then figure out the best way to talk to you guys about it. So that’s been something we’ve been very, very pleased with overall. And your second question, sorry?
Bill Sutherland: Multi-specialty.
Eric Evans: Multi-specialty. Yeah. So multi-specialty, so you should know the vast majority of our SEs today are multi-specialty. And we do still have some single-specialty ASCs in both ophthalmology and GI. But yeah, the vast majority are multi-specialty. Wherever we can, we turn the single specialty in the multi-specialty. And if you look forward, I would say what’s interesting about our de novos, I think they will ultimately be multi-specialty. Many of them are ortho-focused. What that allows you, though, is bigger rooms, you’re building for more complex cases, which does allow you to fill in any gaps with other specialties over time. So you might see some of those come out of the gate really, really specialized and taking off on those areas, but we see opportunities there over time to add ad service lines like we always do.
And our bias is definitely towards multi-specialty because it allows us to use all of our different growth tactics and levers, allows us to really, really leverage our recruitment team. And so over time, we would expect that to continue to be the direction.
Bill Sutherland: And so your de novos are more tilted toward MSK than Cardio?
Eric Evans: Yes. More towards MSK than anything else for sure. And like I said, we’re still in the early innings of that. We’re excited about that. There is obviously some cardio there. And look, cardio is one of those ones that it’s going to be, again, — it’s going to be a — big growth number on a next several years in a small in. Guessing when it meets its full potential is a little bit like guessing when orthopedics finally came over the hump. But we do expect to continue to see that take off in the coming years.
Bill Sutherland: Okay. Great. Thanks very much.
Eric Evans: Of course.
Operator: Our final question comes from Ben Hendrix of RBC Capital Markets. Please go ahead.
Ben Hendrix: Hey, thank you. Just a quick follow-up question. Most of my questions have been answered. But you appreciate the commentary, the early commentary on 2024 and the commentary about the strong rate growth being 50-50 core growth and mix with maybe a little bit of bias towards acuity. But any thoughts on how that migrates into your early 2024 commentary? Thanks.
Dave Doherty: Yeah. So it is too early, Ben, for us to talk about 2024. So all we’re going to tell you at this stage is that we are — we do see our growth algorithm continuing. And again, we’ve talked about this theme of consistency, right? That is what we want to be known for. It is also just generally the way this business operates, right? We generally do not have kind of unusual events that cause spikes one way or another. So there’s a degree of predictability that you can assume from what we have accomplished so far this year and that ought to continue into next year. But at this stage, I don’t think we’re going to give — I know we’re not going to give guidance on 2024. We just got to finish doing the work and then making sure we get through our Board before we talk publicly.
Eric Evans: Then what I would reiterate, and we continue to say this, we’re a mid-teens growth company. That’s the expectation. We have the opportunity to do that. We don’t see that changing. There’s nothing, as I said in my prepared remarks, having sat in this seat for four years, I’ve got more opportunities and more levers and more tailwinds than I’ve ever had. And so when we talk about that long-term, mid-teens growth, we’ve got as much confidence in that as we’ve ever had more so. And I’m super excited going into 2024. We’ll share more of that with you obviously in the coming months.
Ben Hendrix: I appreciate that. And just very last one, and apologies if I missed it. Within that double-digit de novo growth, any thoughts on how the mix of that pans out between kind of your consolidated, non-consolidated — consolidated equity method mix going forward? Thanks.
Eric Evans: Yeah. A lot of the de novos, especially early on are going to be non-consolidated. So some of them will be non-consolidated because we have a health system partner, which has unique advantages and probably won’t give us the opportunity to buy up. Some of them are us and docs, where we will have distinct opportunities to buy up. And so — but initially, those will be non-consolidated facilities in general.
Ben Hendrix: Thanks.
Eric Evans: Yep, absolutely.
Operator: Thank you. Ladies and gentlemen, it appears we have reached the end of the question-and-answer session. I will now hand over to management for closing remarks.
Eric Evans: Thank you. And I want to appreciate — really appreciate about engagement today. Before we conclude, I would like to reiterate, just how proud I am of our team of professionals and surgeon partners, who worked so closely together to deliver on our mission, which is to enhance patient quality of life through partnership. Their working contributions allow us to deliver consistent and predictable results that we talked about today and they also support a sustained growth for all of our stakeholders and continue to serve our communities with the highest clinical care in low-cost settings with the convenience and professionalism our facilities are known for. Thank you so much for joining our call today, and hope you have a great day. Thanks.
Operator: Thank you. Ladies and gentlemen, that concludes today’s event. Thank you for attending, and you may now disconnect your lines.
